Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FX-909 in Advanced Solid Malignancies
NCT05929235Phase 1Active, not recruiting
- Sponsor
- Flare Therapeutics
- Start
- Aug 2023
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of FX-909 in solid malignancy and urothelial carcinoma (UC) (3 arms), sponsored by Flare Therapeutics. Primary endpoint: Incidence and severity of adverse events and dose-limiting toxicities. Started Aug 2023; status: active, not recruiting.
02
Drugs
FX-909
03
Conditions
solid malignancyurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05929235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05929235.